ECQ Stock Overview
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally.
Notes are coming soon
PharmAust Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.046|
|52 Week High||AU$0.066|
|52 Week Low||AU$0.032|
|1 Month Change||22.67%|
|3 Month Change||10.84%|
|1 Year Change||-26.98%|
|3 Year Change||-5.15%|
|5 Year Change||27.78%|
|Change since IPO||-95.00%|
Recent News & Updates
|ECQ||DE Pharmaceuticals||DE Market|
Return vs Industry: ECQ underperformed the German Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: ECQ underperformed the German Market which returned -16.4% over the past year.
|ECQ Average Weekly Movement||10.2%|
|Pharmaceuticals Industry Average Movement||5.3%|
|Market Average Movement||5.2%|
|10% most volatile stocks in DE Market||10.3%|
|10% least volatile stocks in DE Market||2.4%|
Stable Share Price: ECQ is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ECQ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer.
PharmAust Limited Fundamentals Summary
|ECQ fundamental statistics|
Is ECQ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ECQ income statement (TTM)|
|Cost of Revenue||AU$314.34k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0053|
|Net Profit Margin||-37.87%|
How did ECQ perform over the long term?See historical performance and comparison